{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:35Z","timestamp":1790727095027,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1053\/j.semnuclmed.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T03:06:21Z","timestamp":1460171181000},"page":"203-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma"],"prefix":"10.1053","volume":"46","author":[{"given":"Jorge A.","family":"Carrasquillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP14481.RA","article-title":"Pheochromocytoma and paraganglioma","volume":"21","author":"Pacak","year":"2015","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jmg.39.3.178","article-title":"Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas","volume":"39","author":"Baysal","year":"2002","journal-title":"J Med Genet"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.01.011_bib4","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1053\/j.semnuclmed.2016.01.011_bib5","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.semnuclmed.2016.01.011_bib6","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose I-131 metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib7","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma\u2014Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib9","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib10","first-page":"100","article-title":"I-131-MIBG treatment of pheochromocytoma: Low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.01.011_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of I-131-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry","volume":"61","author":"Yoshinaga","year":"2014","journal-title":"Endocr J"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant metaiodobenzylguanidine (I-131-MIBG): A comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib13","first-page":"292","article-title":"Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine","volume":"35","author":"Fischer","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with I-131-meta-iodobenzylguanidine (I-131-MIBG)","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib16","first-page":"288","article-title":"131IMetaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma","volume":"35","author":"Lumbroso","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198107023050103","article-title":"Scintigraphic localization of pheochromocytoma","volume":"305","author":"Sisson","year":"1981","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib19","first-page":"349","article-title":"Radiolabeled adrenergic neuron-blocking agents\u2014Adrenomedullary imaging with I-131 iodobenzylguanidine","volume":"21","author":"Wieland","year":"1980","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib20","first-page":"197","article-title":"Radiopharmaceutical treatment of malignant pheochromocytoma","volume":"25","author":"Sisson","year":"1984","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/eje.1.01987","article-title":"Different expression of catecholamine transporters in phaeochromocytomas from patients with Von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2","volume":"153","author":"Huynh","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters","volume":"89","author":"Kolby","year":"2003","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/ERC-10-0175","article-title":"Expression of somatostatin receptors, dopamine D-2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas","volume":"18","author":"Saveanu","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2967\/jnumed.115.154815","article-title":"Semiquantitative I-123-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters","volume":"56","author":"van Berkel","year":"2015","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib25","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/jc.2009-2352","volume":"95","author":"Fottner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib26","first-page":"973","article-title":"Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison","volume":"28","author":"Bomanji","year":"1987","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","article-title":"Malignant pheochromocytoma: Predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center","volume":"39","author":"Szalat","year":"2011","journal-title":"Endocrine"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib28","first-page":"358","article-title":"Imaging the primate adrenal-medulla with [I-123] and [I-131] metalodobenzylguanidine\u2014Concise communication","volume":"22","author":"Wieland","year":"1981","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.2910480421","article-title":"Pharmacokinetics and intracellular-distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in sk-n-sh neuroblastoma and pc-12 pheochromocytoma cells","volume":"48","author":"Smets","year":"1991","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.2910470119","article-title":"Metaiodobenzylguanidine uptake and storage in the human neuroblastoma cell-line sk-n-be(2c)","volume":"47","author":"Lashford","year":"1991","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib31","first-page":"341","article-title":"The evolution in the use of MIBG in more than 25 years of experimental and clinical applications","volume":"52","author":"Rufini","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1053\/j.seminoncol.2010.10.015","article-title":"Molecular imaging of neuroendocrine tumors","volume":"37","author":"Carrasquillo","year":"2010","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.semnuclmed.2011.06.001","article-title":"Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: Program planning and initial experience","volume":"41","author":"Shusterman","year":"2011","journal-title":"Semin Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ejca.2008.01.010","article-title":"Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age","volume":"44","author":"de Kraker","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0167-8140(92)90199-5","article-title":"The treatment of resistant neuroblastoma with I-131 metaiodobenzylguanidine\u2014Alternative methods of dose prescription","volume":"25","author":"Fielding","year":"1992","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00000421-199206000-00009","article-title":"131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma","volume":"15","author":"Hutchinson","year":"1992","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0959-8049(95)00048-N","article-title":"A new approach in the treatment of stage-IV neuroblastoma using a combination of I-131 metaiodobenzylguanidine (MIBG) and cisplatin","volume":"31A","author":"Mastrangelo","year":"1995","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00000421-199908000-00008","article-title":"Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy","volume":"22","author":"Sisson","year":"1999","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.apradiso.2004.07.001","article-title":"No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue","volume":"62","author":"Vaidyanathan","year":"2005","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib40","first-page":"1088","article-title":"No-carrier-added iodine-131-MIBG\u2014Evaluation of a therapeutic preparation","volume":"36","author":"Mairs","year":"1995","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00006231-199404000-00157","article-title":"Carrier-free I-131 metaiodobenzylguanidine\u2014Comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine","volume":"15","author":"Mairs","year":"1994","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/0959-8049(95)00052-K","article-title":"Enhanced tumor uptake and in-vitro radiotoxicity of no-carrier-added [I-131] metaiodobenzylguanidine\u2014Implications for the targeted radiotherapy of neuroblastoma","volume":"31A","author":"Mairs","year":"1995","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/cbr.2008.0584","article-title":"Radiation dosimetry, pharmacokinetics, and safety of ultratrace (TM) iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"Coleman","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/cbr.2009.0695","article-title":"Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution","volume":"25","author":"Barrett","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00006231-200005000-00005","article-title":"No-carrier-added I-123-MIBG: An initial clinical study in patients with phaeochromocytoma","volume":"21","author":"Owens","year":"2000","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib46","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for I-131-meta-iodobenzylguanidine (I-131-MIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib47","first-page":"481","article-title":"Labetalol reduces I-131 MIBG uptake by pheochromocytoma and normal-tissues","volume":"30","author":"Khafagi","year":"1989","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib48","first-page":"308","article-title":"I-131 metaiodobenzylguanidine therapy of malignant pheochromocytoma: Interference of medication","volume":"35","author":"Hoefnagel","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib49","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00003072-199204000-00011","article-title":"Metaiodobenzylguanidine scintigraphy of a patient with pheochromocytoma on labetalol therapy","volume":"17","author":"Morais","year":"1992","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00006231-199207000-00006","article-title":"A pharmacological guide to medicines which interfere with the biodistribution of radiolabeled metaiodobenzylguanidine","volume":"13","author":"Solanki","year":"1992","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib51","first-page":"538","article-title":"Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells","volume":"24","author":"Babich","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"7-8","key":"10.1053\/j.semnuclmed.2016.01.011_bib52","first-page":"345","article-title":"Modification by nifedipine of I-131-meta-iodobenzylguanidine kinetics in malignant pheochromocytoma","volume":"14","author":"Blake","year":"1988","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib53","first-page":"37","article-title":"Metabolism of I-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma","volume":"27","author":"Mangner","year":"1986","journal-title":"J Nucl Med"},{"issue":"19","key":"10.1053\/j.semnuclmed.2016.01.011_bib54","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJM198011063031903","article-title":"Suppression of thyroid radioiodine uptake by various doses of stable iodide","volume":"303","author":"Sternthal","year":"1980","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib55","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00004032-200006000-00008","article-title":"Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by I-131 from radioactive fallout","volume":"78","author":"Zanzonico","year":"2000","journal-title":"Health Phys"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib56","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/1097-0142(19910215)67:4<922::AID-CNCR2820670411>3.0.CO;2-D","article-title":"Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine","volume":"67","author":"Garaventa","year":"1991","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib57","first-page":"300","article-title":"Preliminary results of 131metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma","volume":"35","author":"Colombo","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib58","first-page":"207","article-title":"Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma: Seven years after","volume":"35","author":"Hor","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pbc.20240","article-title":"Tumor response and toxicity with multiple infusions of high dose I-131-MIBG for refractory neuroblastoma","volume":"44","author":"Howard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.01.011_bib60","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.1992.10.12.1889","article-title":"Phase I\/II study of I-131 metaiodobenzylguanidine in chemoresistant neuroblastoma\u2014A United Kingdom children\u2019s cancer study-group investigation","volume":"10","author":"Lashford","year":"1992","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.01.011_bib61","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2002.08.124","article-title":"Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma","volume":"20","author":"Yanik","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib62","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.surg.2004.06.050","article-title":"The palliative role of I-131-MIBG and In-111-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms","volume":"136","author":"Pasieka","year":"2004","journal-title":"Surgery"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.01.011_bib63","first-page":"1660","article-title":"Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy","volume":"45","author":"Nguyen","year":"2004","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.1984.tb00074.x","article-title":"Malignant pheochromocytoma\u2014Clinical, biochemical and scintigraphic characterization","volume":"20","author":"Shapiro","year":"1984","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib65","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors","volume":"14","author":"Taal","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib66","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/ejso.2001.1132","article-title":"I-131-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome","volume":"27","author":"Pathirana","year":"2001","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.01.011_bib67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF03345807","article-title":"Malignant pheochromocytoma\u2014Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases","volume":"15","author":"Schlumberger","year":"1992","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib68","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with I-131 metaiodobenzylguanidine: Results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0936-6555(02)00273-X","article-title":"Treatment of neuroendocrine tumours in adults with I-131-MIBG therapy","volume":"15","author":"Bomanji","year":"2003","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00256489","article-title":"The role of I-131 metaiodobenzylguanidine in the diagnosis and therapy of carcinoids","volume":"13","author":"Hoefnagel","year":"1987","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pbc.25250","article-title":"Radiation exposure to comforters and carers during paediatric molecular radiotherapy","volume":"62","author":"Gains","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.01.011_bib72","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0b013e31829af3c8","article-title":"Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving I-131-metaiodobenzylguanidine (I-131-MIBG) therapy","volume":"38","author":"Markelewicz","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib73","first-page":"361","article-title":"Management of malignant phaeochromocytoma: A retrospective review of the use of MIBG and chemotherapy in the West Midlands","volume":"13","author":"Hartley","year":"2001","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose I-131-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.01.011_bib75","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2006.09.3484","article-title":"Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma","volume":"25","author":"Matthay","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib76","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02285457","article-title":"Dosimetry of I-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma\u2014Results of a UK study","volume":"18","author":"Fielding","year":"1991","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cbr.2005.20.195","article-title":"Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma","volume":"20","author":"Gaze","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.01.011_bib78","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1118\/1.3480965","article-title":"Radiation dose estimation using preclinical imaging with I-124-metaiodobenzylguanidine (MIBG) PET","volume":"37","author":"Lee","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0360-3016(89)90391-X","article-title":"Calculating radiation absorbed dose for pheochromocytoma tumors in 131-I MIBG therapy","volume":"17","author":"Koral","year":"1989","journal-title":"Int J Radiat Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib80","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1118\/1.4921807","article-title":"Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with I-131-metaiodobenzylguanidine with implications for the activity to administer","volume":"42","author":"Minguez","year":"2015","journal-title":"Med Phys"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.01.011_bib81","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/00006231-199310000-00004","article-title":"Treatment of malignant pheochromocytoma, paraganglioma and carcinoid-tumors with I-131 metaiodobenzylguanidine","volume":"14","author":"Bomanji","year":"1993","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib82","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.mnm.0000184941.06123.b9","article-title":"Long-term efficacy of low activity meta-[I-131]iodobenzylguanidine therapy in patients with disseminated neuroendocrine turnours depends on initial response","volume":"26","author":"Buscombe","year":"2005","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib83","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jcem-72-2-455","article-title":"Use of m-[I-131]iodobenzylguanidine in the treatment of malignant pheochromocytoma","volume":"72","author":"Krempf","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib84","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.nucmedbio.2008.05.005","article-title":"Meta I-131 iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglionna","volume":"35","author":"Goldsby","year":"2008","journal-title":"Nucl Med Biol"},{"issue":"22","key":"10.1053\/j.semnuclmed.2016.01.011_bib85","first-page":"6147","article-title":"Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients","volume":"47","author":"Ehninger","year":"1987","journal-title":"Cancer Res"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib86","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/BF02574771","article-title":"The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma","volume":"13","author":"Lashford","year":"1988","journal-title":"Eur J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.01.011_bib87","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00006231-199509000-00007","article-title":"Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance","volume":"16","author":"Wafelman","year":"1995","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib88","first-page":"544","article-title":"Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours","volume":"24","author":"Wafelman","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib90","first-page":"1058","article-title":"Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: Risk versus benefit","volume":"37","author":"Tristam","year":"1996","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/cbr.2007.301","article-title":"Dosimetry for fractionated I-131-MIBG therapies in patients with primary resistant high-risk neuroblastoma: Preliminary results","volume":"22","author":"Buckley","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib92","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mpo.2950150417","article-title":"Treatment of neuroblastoma with I-131 metaiodobenzylguanidine","volume":"15","author":"Troncone","year":"1987","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol-Canc"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.01.011_bib94","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-011-1872-3","article-title":"Clinical significance of 2-18F fluoro-2-deoxy-d-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma","volume":"38","author":"Nakazawa","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib95","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/ejso.2001.1225","article-title":"[I-131]MIBG radionuclide therapy in carcinoid syndrome","volume":"28","author":"Taal","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib96","first-page":"77","article-title":"Role of I-131-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours\u2014Experience of the National Cancer Institute of Milan","volume":"44","author":"Castellani","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib97","series-title":"Pheochromocytoma","first-page":"465","article-title":"Malignant pheochromocytomas and paragangliomas\u2014A phase II study of therapy with high-dose I-131-metaiodobenzylguanidine (I-131-MIBG), vol 1073","author":"Fitzgerald","year":"2006"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib98","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"Safford","year":"2003","journal-title":"Surgery"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2012.30.15_suppl.e13592","article-title":"Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma\/paraganglioma (Pheo)","volume":"30","author":"Pryma","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.01.011_bib100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","article-title":"Prognostic values of initial responses to low-dose I-131-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma","volume":"27","author":"Wakabayashi","year":"2013","journal-title":"Ann Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","article-title":"Management of metastatic phaeochromocytoma and paraganglioma: Use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre","volume":"108","author":"Rutherford","year":"2015","journal-title":"QJM"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2011.29.15_suppl.2526","article-title":"High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations","volume":"29","author":"Jawed","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib103","first-page":"7","article-title":"Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P\/PG): Preliminary results","volume":"33","author":"Pichun","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib104","article-title":"Combined treatment with 131I-MIBG and sunitinib induces remission in a patient with metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation","author":"Makis","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.01.011_bib105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mpo.2950180208","article-title":"Familial pheochromocytoma\u2014Successful treatment with I-131 MIBG","volume":"18","author":"Goncalves","year":"1990","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.01.011_bib106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with I-131-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib107","first-page":"280","article-title":"Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma","volume":"35","author":"Lewington","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib108","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00043426-200307000-00009","article-title":"Secondary myelodysplastic syndrome and leukemia following I-131-metaiodobenzylguanidine therapy for relapsed neuroblastoma","volume":"25","author":"Weiss","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.01.011_bib109","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/pbc.21391","article-title":"Transient sialoadenitis: A complication of I-131-metaiodobenzylguanidine therapy","volume":"50","author":"Modak","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1055\/s-0032-1311634","article-title":"Proteinuria in metastatic pheochromocytoma is associated with an increased risk of acute respiratory distress syndrome, spontaneously or after therapy with I-131-meta-iodobenzylguanidine (I-131-MIBG)","volume":"44","author":"Porzig","year":"2012","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.01.011_bib111","first-page":"1082","article-title":"In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas","volume":"74","author":"Reubi","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.01.011_bib112","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.01.011_bib113","first-page":"1599","article-title":"Effects of therapy with [Lu-177-DOTA(0),Tyr(3)] octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.01.011_bib114","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.01.011_bib115","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib116","first-page":"491","article-title":"Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?","volume":"1073","author":"Kolby","year":"2006"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.01.011_bib117","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.nucmedbio.2008.07.005","article-title":"Hydroxytyrosol increases norepinephrine transporter function in pheochromocytoma cells","volume":"35","author":"Luzon-Toro","year":"2008","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.01.011_bib118","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1677\/ERC-10-0090","article-title":"Increased uptake of I-123 meta-iodobenzylguanidine, F-18 fluorodopamine, and H-3 norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors","volume":"18","author":"Martiniova","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2016.01.011_bib119","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/MNM.0b013e32834bad97","article-title":"I-131 Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies","volume":"32","author":"Rachh","year":"2011","journal-title":"Nucl Med Commun"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981600012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981600012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T10:20:52Z","timestamp":1600424452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129981600012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S000129981600012X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.01.011","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}